Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations

Breadcrumb

  1. Emmes Group

Severity of RSV LRI hospitalizations in 33 to 35 week and 36 week gestational age infants

Go back to Resources

Severity of RSV LRI hospitalizations in 33 to 35 week and 36 week gestational age infants

Authors:

Location:

Go back to Resources

Safety and Immunogenicity of a Recombinant Hemagglutinin Vaccine for H5 Influenza in Humans

Go back to Resources

Safety and Immunogenicity of a Recombinant Hemagglutinin Vaccine for H5 Influenza in Humans

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

Go back to Resources

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Go back to Resources

Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Risk factors for anemia during erythropoietin therapy among pediatric dialysis patients: a North American Pediatric Cooperative Study (NAPRTCS) Report

Go back to Resources

Risk factors for anemia during erythropoietin therapy among pediatric dialysis patients: a North American Pediatric Cooperative Study (NAPRTCS) Report

Authors:

Location:

Go back to Resources

Risk factors associated with age-related nuclear and cortical cataract - A case-control study in the age-related eye disease study. AREDS Report No. 5

Go back to Resources

Risk factors associated with age-related nuclear and cortical cataract - A case-control study in the age-related eye disease study. AREDS Report No. 5

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Rejection profile of recent pediatric renal transplant recipients compared with historical controls: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Go back to Resources

Rejection profile of recent pediatric renal transplant recipients compared with historical controls: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years

Go back to Resources

Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Pretransplant inflammation and renal allograft survival: The role of recipient cytomegalovirus (CMV) serostatus and dialysis modality

Go back to Resources

Pretransplant inflammation and renal allograft survival: The role of recipient cytomegalovirus (CMV) serostatus and dialysis modality

Authors:

Location:

Go back to Resources

Post-transplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Go back to Resources

Post-transplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 130
  • Page 131
  • Page 132
  • Page 133
  • Current page 134
  • Page 135
  • Page 136
  • Page 137
  • Page 138
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • Terms of Use
  • ISO Certification